GlobeNewswire

Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs

Share

PRESS RELEASE

May20, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announcedthat it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE™ database. The company also presented data from its ion channel pipeline programs, SAN711 and SAN903.

A replay of the event is available on the Investors section of the Saniona website, under Events and Presentations, and here: https://media.rampard.com/20210520/.

“Our industry-leading ion channel drug discovery engine has enabled us to build a diverse pipeline of highly selective compounds with the potential to address unmet needs across a variety of diseases,” said Rami Levin, President and Chief Executive Officer of Saniona. “We were pleased to present our proprietary technology, providing new details on preclinical candidates SAN711 and SAN903, which demonstrate the power of our discovery engine to generate a steady source of preclinical candidates that are rapidly advancing towards the clinic.”

Saniona’s ion channel drug discovery engine combines in-house expertise in chemistry, precision biology, in vivo stability/distribution, target engagement, in vivo pharmacology, and artificial intelligence to accelerate the discovery of highly selective, subtype-specific, and state-dependent ion channel modulators. The core of this engine is Saniona’s proprietary IONBASE database, which contains structure-activity data for more than 120,000 compounds. Of these, 20,000 are Saniona’s proprietary compounds, generated over 20 years and enriched for optimal ion channel modulation.

SAN711 is a first-in-class drug candidate that selectively enhances the effects of GABA-A on α3 containing receptors. This selectivity is ideal for rare neuropathic diseases and may allow SAN711 to avoid the typical adverse effects associated with non-selective GABA-A activation such as such as sedation, motoric instability, cognitive impairment, abuse liability and physical dependence. During the R&D Day event, Saniona presented preclinical data demonstrating efficacy from in vivo models for trigeminal neuralgia, a rare form of neuropathic pain. After acute dosing, SAN711 reduced pain in a dose-dependent manner, with the highest dose achieving pain relief similar to the standard of care carbamazepine, which has numerous serious side effects. After chronic dosing, SAN711 was demonstrated to prevent the development of pain, and also to maintain efficacy over time. In another preclinical model of chronic pain in which SAN711 was compared to morphine, SAN711 maintained efficacy over seven days of dosing, while the initial efficacy of morphine was completely eradicated due to tolerance over the same time period. Data comparing SAN711 to the non-selective GABA-A activator diazepam demonstrated that SAN711 did not induce the sedation seen with diazepam. Saniona expects SAN711 to enter a Phase 1 study in healthy volunteers in mid-2021, with data expected in early 2022.

SAN903 is a novel inhibitor of the calcium-activated potassium ion channel, KCa3.1, that is in development for the treatment of rare inflammatory and fibrotic disorders. Data presented during the R&D Day event demonstrated the efficacy of SAN903 in multiple in vitro and in vivo models of inflammation and fibrosis. Data presented at the recent American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021 demonstrated that SAN903 reduced inflammation and fibrosis with greater efficacy than two marketed products, nintedanib and pirfenidone, in an in vivo model of idiopathic pulmonary fibrosis. Saniona expects to initiate a Phase 1 study evaluating SAN903 in healthy volunteers by mid-2022.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

This information was submitted for publication, through the agency of the contact persons set out above, at 20.30CEST on May20, 2021.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

On substantial participation16.6.2021 19:10:00 CEST | Press release

JSC Olainfarm has received announcements on substantial participation from Anna Emīlija Maligina, SIA “OLMAFARM” and SIA “FARMA FUND”. The received announcements (in Latvian) are attached. Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Phone: +371 29178878 Email: janis.dubrovskis@olainfarm.com Attachments Pazinojums_lidzdaliba_SIA Farma Fund_Olainfarm_AEM_OLMAFARM_2021_06_16.docxPazinojums_lidzdaliba_SIA OLMAFARM_Olainfarm_2021_06_16.docxPazinojums_lidzdaliba_AEM_Olainfarm_2021_06_16.docx

GeoJunxion (GOJXN.AS) announces the nomination of a new CEO and CBO16.6.2021 18:00:00 CEST | Press release

Capelle aan den IJssel, The Netherlands – 16 June 2021 – GeoJunxion (GOJXN.AS) is pleased to announce today that the Supervisory Board has decided to nominate Mr. I. Vleeschouwers as its new CEO, and Mr. F. Altamura as its new CBO (Chief Business Officer). Ivo Vleeschouwers currently serving as GeoJunxion’s CFO, has been nominated as permanent CEO. He will be combining the CEO and CFO functions going forward. Mr. Vleeschouwers together with the former CEO (Mr. Jaccoud), has been an integral part in spearheading GeoJunxion’s transformation from a traditional digital map supplier, focused on one-off large deals, to a premium location content and location intelligence service provider, with a “data as a service” revenue model. In light of the recent successes of this on-going change such as the closing of location intelligence service contracts for a value exceeding Euro 600K (see press release dated 6 May 2021) and increased market interest in the new product portfolio (Eco Alert Zones a

Staten lånar 10 miljarder kronor på 50 år till 1,386 % ränta16.6.2021 18:00:00 CEST | Pressemelding

Statenlånar 10 miljarder kronor på 50 år till 1,386% ränta Riksgälden lånadei dag upp 10 miljarder kronor till en ränta på 1,386 procent i den planerade emissionen av en50-årig statsobligation. Den nya obligationen blir det längsta låneti Sveriges statsskuld. Totalt deltog ett 80-tal investerare med en budvolym på drygt 52 miljarder kronor i emissionen som genomfördes som en syndikering. Det innebär att en grupp banker sålde obligationen till villkor som Riksgälden godkänt. Obligationen prissattes till 45 räntepunkter över marknadsräntan på den tidigare längsta svenska statsobligationen som förfaller om drygt 24 år. – Jag är glad att vi har kunnat förlänga den svenska statspapperskurvan till 50 år genom denna transaktion. Med Sveriges starka statsfinanser som grund visar vi än en gång att Riksgälden kan attrahera en bred investerarbas, säger Johan Bergström, tillförordnad upplåningschef på Riksgälden. Riksgälden kommer att bygga upp den utestående volymen i den nya obligationen SGB 106

Sweden raises SEK 10 billion at 1.386 % with 50-year bond16.6.2021 18:00:00 CEST | Press release

Sweden raises SEK 10 billion at1.386%with 50-year bond The Kingdom of Sweden raised SEK 10 billion at a yield of 1.386 per cent in the planned sale of a 50-year government bond. The new bond will be the longest outstanding loan in Sweden’s central government debt. More than 80 investors participated in the syndicated sale with the total bid volume reaching above SEK 52 billion. Syndication means that a group of banks executes the transaction at terms approved by the issuer. The final pricing was fixed at 45 basis points above the yield on the Swedish government bond that was formerly the longest, maturing in just over 24 years. – I am pleased that we were able to extend the Swedish government bond curve to 50 years through this transaction. With Sweden’s strong state finances as a foundation, we have again shown that we can attract a broad investor base, says Johan Bergström, Acting Head of Funding at the Swedish National Debt Office. The Debt Office will gradually build up the outstan

Halmstads Energi och Miljö strengthens power grid for the future – with data analytics16.6.2021 14:23:17 CEST | Press release

Having a security of supply in the power grid of 99,99 percent does not make Halmstads Energi och Miljö AB (HEM) to sit back and relax. Instead, the regional Swedish energy company has declared to make digitalization of the power grid their next step forward. Installing the dInsight Analytics Platform from Dlaboratory Sweden AB (publ) has allowed the company to analyze grid data in-depth and take proactive measures to prevent outages and make grid investments. - The advantage of dLab’s system is that we can find faults in the grid, incidents, and disturbances, before they develop into major outages. This is how we want to work, proactively, before anything has happened, says Jonas Stenberg, electrical engineer at Halmstads Energi och Miljö. The collaboration between HEM and dLab started out as a pilot project in 2018 but by now dLab’s digital solution covers about 70 percent of HEM’s power grid. - It is truly inspiring to learn about HEM’s ambitions within digitalization, and their det

Skyharbour Expands its Current Drill Program at its High Grade Moore Uranium Project, Saskatchewan16.6.2021 14:00:00 CEST | Press release

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V:SYH)(OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce that it is expanding its current diamond drilling program at its flagship 35,705 hectare Moore Uranium Project, located approximately 15 kilometres east of Denison Mine's Wheeler River project and near regional infrastructure on the southeast side of the Athabasca Basin, Saskatchewan. The current drilling program at Moore is progressing well and has provided significant encouragement to expand the current 3,500 metres drilling program to a total of 5,000 metres in 12 to 14 holes. This fully funded and permitted program will focus on following-up on existing unconformity and basement-hosted targets along the high grade Maverick structural corridor as well as newly defined targets at the Grid Nineteen area. Moore Uranium Project Claims Map: https://skyharbourltd.com/_resources/maps/MooreLakeRegionalTenure-v1.jpg Winter/S